Aveo Pharmaceuticals, Inc.

Xoma Technology Ltd.

Novartis Ag

Xoma Technologies, Ltd.

Bijan Etemad-Gilbertson

William M Winston, Jr

Jeno Gyuris

Lyne Breault

Jie Lin

May Han

S Kirk Wright

Christine Knuehl

Arnold H Horwitz

Nicole Haubst

Joy Gispati Ghosh

Michael Stefanidakis

Chad Eric Bigelow

Stephen Hedrick Poor

Engin Toksoz

Nina Moker

James Edgar Chastain

Michael Zbigniew Twarog

Nalini Velamur Rangaswamy

Yubin Qiu

Andrew Anh Nguyen

Ganesh Rajan Iyer

Shawn Michael Hanks

Kirk Lee Clark

Ana Maria Carrion

William M Winston

The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.

Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules

The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

Nucleic acid encoding hepatocyte growth factor (HGF) binding proteins

Hepatocyte growth factor (HGF) binding proteins

[object Object]

Hepatocyte growth factor (HGF) binding antibody

Growing community of inventors

Jamaica Plain, MA, United States of America

Bijan Etemad-Gilbertson